

U-CyTech B.V.

Yalelaan 42
3584 CM Utrecht
The Netherlands
+31 85 073 1460
info@ucytech.com
www.ucytech.com

Data sheet

ICE Peptide Pool

Peptide pool of 32 HLA class I restricted T cell epitopes of human Influenza A virus, Cytomegalovirus and Epstein-Barr virus.

Cat. No

CT387

Specificity

Intended for use as an antigen-specific positive control in for example the human IFN- γ , IL-2 and G-CSF ELISPOT assay. The peptide pool consists of 32 peptides, each corresponding to 13 HLA class I restricted CD8⁺ T cells epitopes from human Influenza A virus (Flu), Cytomegalovirus (CMV) and Epstein-Barr virus (EBV). (Reference: Currier, J.R. *et al.* 2002. J. Immunol. Methods 260: 157-172)

Application

Reconstitute the lyophilized content by injecting 250 μ l of sterile distilled water into the vial. Mix the solution gently for approximately 15 seconds and allow it to stand for 2 minutes at room temperature. Avoid vigorous shaking.

Working concentration: 40x in culture medium containing human PBMC
Recommended peptide concentration: 0.5 μ g peptide/ml culture medium
Recommended cell concentration: 2×10^5 human PBMC/well
Recommended culture volume in ELISPOT plate: 100 μ l/well

Contents

Lyophilized ICE peptide pool: 32 x 5 μ g peptide/vial
Buffer prior to lyophilization: 0.25 ml PBS + 125 mM trehalose.
Preservative free

Contained peptides

VSDGGPNLY (Influenza A, HLA-A1), CTEKLSDY (Influenza A, HLA-A1), GILGFVFTL (Influenza A, HLA-A2), FMYSDHFH (Influenza A, HLA-A2), CLGGLTMM (EBV, HLA-A2), GLCTLVAML (EBV, HLA-A2), NLVPMVATV (CMV, HLA-A2), KTGGPYKR (Influenza A, HLA-A68), RVLSFIKGTK (Influenza A, HLA-A3), ILRGSVAHK (Influenza A, HLA-A3), RVRAYTSK (EBV, HLA-A3), RLRAEAQVK (EBV, HLA-A3), SIIPSGPLK (Influenza A, HLA-A3/A11/A6), AVFDRKSDAK (EBV, HLA-A11), IVTDFSVIK (EBV, HLA-A11), ATIGTAMYK (EBV, HLA-A11), DYCYNLNKEF (EBV, HLA-A24), LPFDKTTVM (Influenza A, HLA-B7), RPPFIRRL (EBV, HLA-B7), ELRSRYWAI (Influenza A, HLA-B8), RAKFKQLL (EBV, HLA-B8), FLRGRAYGL (EBV, HLA-B8), QAKWRLQTL (EBV, HLA-B8), SDEEEAIVAYTL (CMV, HLA-B18), SRYWAIRTR (Influenza A, HLA-B27), ASCMGLIY (Influenza A, HLA-B27), RRIYDLIEL (EBV, HLA-B27), YPLHEQHGM (EBV, HLA-B35), IPSINVHHY (CMV, HLA-B35), EENLLDFVRF (EBV, HLA-B44), EFFWDANDIY (CMV, HLA-B44), TPRVTGGGAM (CMV, HLA-B7).

Sterility

Membrane filtered (0.2 μ m)

Packaging

Brown glass bottle

Storage

The lyophilized peptide pool can be safely stored at 2 to 8 °C for a specified period of time (expiration date printed on vial). After reconstitution, it is strongly recommended to divide the reconstituted peptides into small aliquots for single use. These aliquots should be stored at -32 to -18 °C. Under these conditions the peptides are stable for at least two years.

General

Clear powder (barely visible). After reconstitution: a clear solution. Do not use if the solution is or has become turbid.

Safety

The product is not classified as hazardous according to Regulation (EC) No 1272/2008. Consult the safety data sheet (SDS) for further information regarding hazards and safe handling. The SDS can be found on our website www.ucytech.com.

